About UsHIVandHepatitis.com 2017 Conference Coverage
- Details
- Category: HIV Treatment
- Published on Saturday, 30 December 2017 00:00
- Written by HIVandHepatitis.com
Article listings by topic for HIVandHepatitis.com conference coverage in 2017, including the Conference on Retroviruses and Opportunistic Infections, EASL International Liver Congress, IAS Conference on HIV Science, and AASLD Liver Meeting.
Top 10 HIV and Hepatitis Stories of 2017
- Details
- Category: HIV Treatment
- Published on Friday, 29 December 2017 00:00
- Written by Liz Highleyman
For our last issue, HIVandHepatitis.com reviews some the year's major HIV, viral hepatitis, and related news highlights. As we enter 2018, antiretroviral treatment for HIV is about as good as it can get, use of PrEP for HIV prevention is expanding rapidly, and most people can be cured of hepatitis C with 2 or 3 months of well-tolerated therapy. But these advances are still not reaching everyone who needs them. The search for a functional cure for HIV, better treatments for hepatitis B, and management of fatty liver disease remain major challenges for the year ahead.
BHIVA 2017: Despite Reassuring Data, We Can’t Yet Say U=U for Breastfeeding
- Details
- Category: Pregnancy & HIV MTCT
- Published on Thursday, 30 November 2017 00:00
- Written by Roger Pebody
While effective HIV treatment greatly reduces the risk of onward transmission during breastfeeding, it does not appear that the risk is zero, a leading pediatrician told the British HIV Association (BHIVA) conference last month in London last week.
A Message To Our Readers
- Details
- Category: HIV Treatment
- Published on Friday, 29 December 2017 00:00
- Written by Liz Highleyman
As of the new year, HIVandHepatitis.com will be transferred to Smart + Strong, the publisher of POZ, Hep, Real Health, and the new Cancer Health magazines and websites. HIVandHepatitis.com will remain online as an archive for the near future but will not publish new content. HIVandHepatitis.com editor Liz Highleyman is now editor-in-chief of Cancer Health.
FDA Approves Juluca Dual Single-Tablet Regimen
- Details
- Category: Approved HIV Drugs
- Published on Thursday, 30 November 2017 00:00
- Written by HIVandHepatitis.com
On November 21, the U.S. Food and Drug Administration approved Juluca, a fixed-dose coformulation containing dolutegravir and rilpivirine, for the treatment of adults with HIV who have undetectable viral load on their current antiretroviral regimen. Juluca, a joint product of ViiV Healthcare and Janssen, is the first complete single-tablet regimen containing only 2 drugs.
HIV Cure Summit Hears About New Remission Case
- Details
- Category: Search for a Cure
- Published on Thursday, 14 December 2017 00:00
- Written by Liz Highleyman
The past year brought no major breakthroughs in the search for an HIV cure, but a growing understanding of how the virus hides in the body bring us closer to strategies for long-term remission, researchers and advocates said at the 2017 HIV Cure Summit in San Francisco.
EACS 2017: New European Guidelines Cover HIV, Hepatitis C, and Related Conditions
- Details
- Category: HIV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Keith Alcorn
Everyone with HIV and hepatitis C virus (HCV) coinfection should receive direct-acting antiviral therapy for hepatitis C and should receive the same treatment regimens for hepatitis C as people with HCV monoinfection, new European guidelines issued at the 16th European AIDS Conference recommend.
San Francisco Getting to Zero Update Hears U=U Message
- Details
- Category: Treatment as Prevention
- Published on Thursday, 07 December 2017 00:00
- Written by Liz Highleyman
San Francisco continues to make progress in reducing new HIV infections and expanding access to early treatment, according to a World AIDS Day update on the city's Getting to Zero initiative, held on November 29, 2017.
EACS 2017: Fostemsavir Controls Viral Load in Half of People with Highly Drug-Resistant HIV
- Details
- Category: HIV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Keith Alcorn
Fostemsavir, a new experimental attachment inhibitor, suppressed viral load in over half of participants with extensive drug resistance when added to a background regimen selected by resistance testing, Max Lataillade of ViiV Healthcare reported at the recent 16th European AIDS Conference in Milan.
Web Design and Development by